Member Info for crumbs

It's a balance isn't it ...In her role as CEO considering we have no RG or CH anymore we could do with that member of the BOD who interacts at least a bit.... For me the no proactive on the MaB deal was telling... now I'm not saying so right now would be any different if she had made that effort but it certainly would have added sp buoyancy at the time.. as for Scancell that deal is significant I know some call it for the upfront but really Scancell gave up very little IP there to get a decent amount ... its not a product it's a target deal... anyways still no investor attracting type events scheduled for this year so again looks like there is 'something' brewing that does not require the tin to be shaken ...

Doubt it. it'll be released due to protocol not to please the market.. once again I think LD does not give one for AIM ...I know that is not much comfort for us pi but you like to think she is so confident of a payoff that it means she doesn't need to worry about the day to day sp performance

Well it is coming!

And for those wondering will it be the same as the AACR poster it won't it will be an update here is the link to ASCOs 2015 SCIB1 submission https://meetings.asco.org/abstracts-presentations/112633

And here is the June 2nd RNS https://www.lse.co.uk/rns/SCLP/scib1-data-update-in-resected-melanoma-patients-hjy697d23akbjyv.html

The data presented is updated from the submission .... we should expect the same from the ModiFy data prof otten will present it ought to be up to date to May (last month).... which I think ties in with scans etc?

It has broken the 15p ceiling next stop a cracking 19p :)

nah but probably quite a few are aware of likelihood of a Friday ASCO RNS including a MoDify update

Glycan and Novel Targets for Bispecific Cancer Therapy

Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, Ltd.

https://www.pegsummiteurope.com/speaker-biographies

On after GenMab

https://www.pegsummiteurope.com/antibody-based-cancer-therapies

ImmunoBody remains our most clinically advanced and IMHO the most low-risk platform for pharma to do a deal on.... as you can pretty much guarantee immune responses in a SCIB trial .... and now the delivery problem has been sorted ...

Yes that is interesting Johnny same as ever till we know we don't know I also noted refrences to unpublished SCIB1 data in that paper...which is also interesting ... as for why Texas hmm maybe?

'Texas Biomed established partnerships with pharmaceutical giant Pfizer and biotechnology company Regeneron Pharmaceuticals, both based in New York. It also worked with Novavax, a biotechnology firm in Maryland, as well as Gilead, a pharmaceutical company in California.

The institute’s staff gained national recognition for its contributions to researching COVID-19 and for helping the government and Big Pharma get therapeutics and vaccines onto market.'

https://www.expressnews.com/sa-inc/article/san-antonio-biomed-research-17856361.php#:~:text=Texas%20Biomed%20established%20partnerships%20with,a%20pharmaceutical%20company%20in%20California.

A staring match...who blinks first

Again I just go off SCIIB1 ASCO history,I expect what the good prof presents at ASCO to be up to date data (May) so we will get that data in the coming RNS it's not about giving the market the news first it's protocol....

Yeah, that is as maybe but what do you anticipate will be in the ASCO RNS this Friday (or poss Mon).... I'm anticipating a Modify data update,should be interesting

Article and more interesting that the Malawian Ministry of Mining post it!.... I think the ministry is very much pro getting the MDAs done

https://www.facebook.com/photo?fbid=246512784692566&set=a.200109085999603

'@BermudaShorts, can you remind us why they didnt commence the larger 80 patient US based trial?'

No! no noooooo! I was enjoying this bank holiday weekend why spoil it with reviving that nightmare:))))

Yeah the BOD have managed to shaft the workforce to shaft the customers and to shaft the shareholders including the biggest holder....yet ST is a hero it's all part of a great plan and well can't we just get back to blaming the workforce that used to make the profit that payed the dividends that rose the SP

Those can't be the real Mr. K's words as those are only to be found on here with him constantly 'playing a blinder' as he peels away GLS from what he considers worthless Royal Mail .... oh well

Certainly it's about recruitment I suppose especially for CPI arm and earlier stage patients as really for them the trial needs to be promoted as beneficial due to those patients not really needing to take the risk

It's a nice vid nothing groundbreaking but does its job I also like the ModiFy logo it's all much like Covidity giving it a branding angle but the most important thing to me is it means the trial is all go it is not a case of scancell needing to quietly run it down .... meaning so far so good it's doing enough to warrant pushing it to its conclusion and hopefully beyond that too... looking forwards to the coming trial update where I believe we will at least with mono HGOC target get to see an emerging pattern....

I think we can agree there will be an ASCO RNS :)

Same again for 2014 https://www.lse.co.uk/rns/SCLP/update-on-phase-12-trial-of-scib1-in-melanoma-aef489rwpuwyrk0.html

I expect a June 2nd ModiFy RNS

I keep telling ...just go back to SCIB1 ASCO presentations... new data RNS for the poster

https://www.lse.co.uk/rns/SCLP/scib1-data-update-in-resected-melanoma-patients-hjy697d23akbjyv.html

I expect the same with Modify it will be the latest data presented

Https://www.windpowermonthly.com/article/1823428/uk-plant-recycle-rare-earth-magnets-key-wind-industry